Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Oncopeptides in connection with its rights issue (2)
Mandate

Vinge has advised Oncopeptides in connection with its rights issue

March 03, 2026 Capital Markets and Public M&A

Vinge has advised Oncopeptides AB (publ) in connection with a partially guaranteed rights issue which is expected to provide Oncopeptides with proceeds of approximately SEK 200 million before deduction of transaction costs.

Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.

Vinge’s team consisted of Dain Hård Nevonen, Joel Magnusson, Amanda Sandström and Johannes Ekbom.

Related

Vinge has represented Anaqua, a portfolio company of Nordic Capital, in connection with the acquisition of Patrix

 Vinge has represented Anaqua, Inc., a portfolio company of Nordic Capital, in connection with the acquisition of Patrix Aktiebolag, provider of IP management software and services. The acquisition is a strategic addition to Anaqua's platform, further expanding its European presence.
April 30, 2026

Vinge advises parts of the consortium in connection with the public takeover offer for Cint

 The public takeover offer was announced by a consortium consisting of Triton Fund 6, Bolero, Patrick Comer and Brett Schnittlich. The offer values all shares in Cint at approximately SEK 1,989 million. The shares in Cint are listed on Nasdaq Stockholm, Mid Cap.
April 27, 2026

Nordea and SEB enters into a SEK 2,000,000,000 credit facility agreement

 On 22 April 2026, Nordea and SEB entered into a credit facility agreement in the aggregate amount of SEK 2,000,000,000 (with an accordion option for an additional SEK 400,000,000) with Humble Group AB (publ).
April 27, 2026